anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This single-center, non-randomized interventional dose-finding phase I trial evaluates the maximal tolerated boost dose with respect to dose limiting toxicities in patients with locally advanced head and neck squamous cell carcinoma (UICC stage III/IVB) with an indication for a primary radiochemotherapy. The primary aim of the trial is to define the maximal tolerated dose in an ADC-based subvolume using an adaptive SBRT-boost areal. Dose-escalated SBRT boost to ADC-high risk volume will be delivered once a week and is defined according to the the actual imaging immediately performed prior to delivery (real-time adaptive) i.e. it can vary from one week to another and it might also be reduced throughout the course of treatment (response adaptive). In case of complete disappearance of high-risk subvolumes sufficient large enough to boost (\<5ml), no further ADC boost but only the floor-boost dose is given. The dose escalation of the ADC-high risk volume boost is graduated in four dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy in a classical 3+3 dose-finding design where 3 patients per radiation dose level are enrolled. Primary endpoint is the dose limiting toxicity, any acute and late non-hematologic grade 4 or 5 related to the radiotherapy intervention, ≥ grade 3 CTC v.5. oral mucositis at 3 months after radiotherapy.
PURPOSE:To use lentinan as a preventive and remedy for infectious diseases of Pseudomonas aeruginosa. CONSTITUTION:A preventive and remedy for infectious diseases of Pseudomonas aeruginosa, containing lentinan. Lentinan is a high polymer glucan having beta-(1-3) bond as a main chain, separated from Lentinus edodes), and well-known (e.g., Japanese patent 49-484, 48-6767) as a carcinostatic agent. This time, it has been newly found that lentinan as a preventive and remedy for infectious diseases of Pseudomonas aeruginosa can be applied to human and animals. Various forms such as oral administration(e.g., tablet, capsule, elixir, etc.), parenteral administration (e.g., sterilized solution, suspension, etc.), etc. can be applied as administration form. A dose is 1-2,000mg/day.
The invention relates to a fitting system for fitting medical accessory carriers, in particular medical accessory containers, for treating a patient. The fitting system has a storage device for a plurality of medical accessories of at least two types, a selecting device for medical accessories, and a fitting region for a medical accessory carrier. Additionally, the fitting system has an accessory database for data sets pertaining to the plurality of medical accessories, said data sets relating to one or more treatments of patients, and a data storage device for the accessory database, said data storage device being designed to store the accessory database. The fitting system additionally has one or more data interfaces, at least one of the data interfaces being designed to receive one or more selection parameters, in particular treatment data or patient data, relating to the treatment of the patient. Finally, the fitting system has a data processing device which is designed to carry out a selection method. The selection method has at least the following method steps: in one method step, one or more accessory set parameters, which characterize a medical accessory set consisting of one or more medical accessories which are suitable for treating the patient, are determined using the accessory database at least on the basis of the selection parameter; and in an additional method step, the selecting device for medical accessories is actuated on the basis of the accessory set parameter. The selecting device for medical accessories is designed to remove the medical accessories of the accessory set out of the storage device according to the actuation and dispense same at the fitting region.
Sleep deprivation (SD) has a wide range of adverse health effects. However, the mechanisms by which SD influences corneal pathophysiology and its post-wound healing remain unclear. This study aimed to examine the basic physiological characteristics of the cornea in mice subjected to SD and determine the pathophysiological response to injury after corneal abrasion. Using a multi-platform water environment method as an SD model, we found that SD leads to disturbances of corneal proliferative, sensory, and immune homeostasis as well as excessive inflammatory response and delayed repair after corneal abrasion by inducing hyperactivation of the sympathetic nervous system and hypothalamic-pituitary-adrenal axis. Pathophysiological changes in the cornea mainly occurred through the activation of the IL-17 signaling pathway. Blocking both adrenergic and glucocorticoid synthesis and locally neutralizing IL-17A significantly improved corneal homeostasis and the excessive inflammatory response and delay in wound repair following corneal injury in SD-treated mice. These results indicate that optimal sleep quality is essential for the physiological homeostasis of the cornea and its well-established repair process after injury. Additionally, these observations provide potential therapeutic targets to ameliorate SD-induced delays in corneal wound repair by inhibiting or blocking the activation of the stress system and its associated IL-17 signaling pathway.
After an initial washout period of 2 weeks, participants randomised to Sequence AB will consume GMP-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis. At the end of 3 months there is a further 2 week washout period with L-AA, after which the participant will consume L-AA for 3 months whilst keeping a food diary and sending blood spots for twice weekly analysis.
The invention relates to a magnetic genetic engineering bacterium, a construction method and application thereof. According to the invention, the magnetosome protein Mms6 is anchored on the surface of bacteria through a bacteria surface display technology, and can be used as a nucleation site of magnetic crystals and a regulator of crystal size/morphology by utilizing the iron binding characteristic of the Mms6C end, so that magnetic particles are formed in situ on the surface of the bacteria, and a magnetic engineering bacterium is constructed. The beneficial effects of the invention are mainly as follows: 1. the modularized surface display system is more flexible to apply, can promote the correct folding of target proteins, and improves the surface display efficiency and the cell activity. 2. The method for constructing the magnetic engineering bacteria by using the bacteria surface display system is simple to operate, and avoids the complicated steps of synthesizing magnetic particles in advance and modifying. 3. The magnetic engineering escherichia coli has strong magnetism, and can be magnetically driven under an external magnetic field.
Dry needling + usual care. Subjects will receive a total of 4 sessions of ultrasound-guided dry needling over 4 weeks, one per week.
Rare cancers collectively account for a significant proportion of the overall cancer burden in Japan. We aimed to describe and examine the incidence of each rare cancer and the temporal changes using the internationally agreed rare cancer classification. Cancer cases registered in regional population-based cancer registries from 2011 to 2015 and the National Cancer Registry (NCR) from 2016 to 2018 were classified into 18 families, 68 Tier-1 cancer groupings, and 216 single cancer entities based on the RARECAREnet list. Crude incidence rates and age-standardized incidence rates (ASR) were calculated for Tier-1 and Tier-2 cancers. The annual percent change and the 95% and 99% confidence limits for annual ASR for each of the 68 Tier-1 cancers were estimated using the log-linear regression of the weighted least squares method. The differences in ASRs between 2011 and 2018 were evaluated as an absolute change. A total of 5,640,879 cases were classified into Tier-1 and Tier-2 cancers. The ASRs of 18 out of 52 Tier-1 cancers in the rare cancer families increased, whereas the ASR for epithelial tumors of gallbladder decreased. The ASRs of 6 out of the 16 Tier-1 cancers in the common cancer families increased, whereas those of epithelial tumors of stomach and liver decreased. There was no significant change in the incidence of the other 40 Tier-1 cancers. The incidence of several cancers increased due to the dissemination of diagnostic concepts, improved diagnostic techniques, changes in coding practice, and the initiation of the NCR.
Ursolic acid (UA), a pentacyclic triterpene, exhibits diverse pharmacological effects, including potential treatment for allergic diseases. It downregulates thymic stromal lymphopoietin (TSLP) and disrupts mast cell signaling pathways. However, the exact molecular mechanism by which UA interferes with mast cell action remains unclear. Therefore, the current study aimed to uncover molecular entities underlying the effect of UA on mast cells and its potential antipruritic effect, specifically investigating its modulation of key molecules such as TRPV4, PAR2, and MRGPRX2, which are involved in TSLP regulation and sensation. Calcium imaging experiments revealed that UA pretreatment significantly suppressed MRGPRX2 activation (and its mouse orthologue MrgprB2), a G protein-coupled receptor predominantly expressed in mast cells. Molecular docking predictions suggested potential interactions between UA and MRGPRX2/MrgprB2. UA pretreatment also reduced mast cell degranulation through MRGPRX2 and MrgprB2-dependent mechanisms. In a dry skin mouse model, UA administration decreased tryptase and TSLP production in the skin, and diminished TSLP response in the sensory neurons. While PAR2 and TRPV4 activation enhances TSLP production, UA did not inhibit their activity. Notably, UA attenuated compound 48/80-induced scratching behaviors in mice and suppressed spontaneous scratching in a dry skin model. The present study confirms the effective inhibition of UA on MRGPRX2/MrgprB2, leading to reduced mast cell degranulation and suppressed scratching behaviors. These findings highlight the potential of UA as an antipruritic agent for managing various allergy- or itch-related conditions.
The invention provides a method for screening a novel coronavirus inhibitor in vitro, belonging to the field of biological analysis and detection. The method screens inhibitor molecules by detecting changes in fluorescence energy resonance transfer (FRET) signals in vitro. The specific method is that firstly, a gene engineering method is used for fusing label proteins on a receptor binding protein (RBD) of the novel coronavirus and an acceptor human angiotensin converting enzyme 2(hACE2), and FRET (fluorescence resonance energy transfer) -acceptor fluorescent micromolecules are respectively used for labeling the two proteins. In solution, excitation with light is initiated by the donor molecule, which emits the acceptor molecule fluorescence due to the interaction of hACE2 and RBD proteins. When a new coronavirus inhibitor is added, hACE2 and RBD proteins are dissociated, and the fluorescence of the molecular acceptor is reduced and the fluorescence of the donor is increased. The method can be used for screening new coronavirus inhibitor molecules in vitro, and has the characteristics of sensitivity and rapidness.
BACKGROUND Persistent truncus arteriosus is a rare congenital cyanotic heart defect characterized by a single ventricular outflow tract. Without surgical intervention, it has a poor prognosis in infancy. Here, we report an adult female patient with uncorrected truncus arteriosus type I, who presented with acute-onset abdominal pain due to torsion of a small bowel gastrointestinal stromal tumor (GIST). CASE REPORT A 41-year-old woman came to our Emergency Department with acute-onset lower abdominal pain for 2 days. Congenital heart disease, truncus arteriosus, had been diagnosed at birth, and there had been no surgical intervention. Abdominal computed tomography revealed a 10×9×12-cm mixed-density mass in the pelvic capacity. Transthoracic echocardiography revealed a 33-mm ventricular septal defect. The ascending aorta originated mainly from the right ventricle, and the pulmonary artery originated from the beginning of the aorta (type I truncus arteriosus, according to Collett and Edwards classification). After a quick and detailed preoperative workup, the patient underwent tumor resection by open surgery with general anesthesia. CONCLUSIONS This is the first case to report emergency surgery for a patient with uncorrected persistent truncus arteriosus due to torsion of a small bowel GIST. A multidisciplinary team with deep understanding of the disease entity was crucial. By considering the fixed hemodynamic and respiratory physiology, overtreatment and unrealistic goals were avoided. Eventually, the patient was discharged after being hospitalized for 2 weeks.
The present invention relates to a conjugate of lidamycin, monoclonal antibodies and Fab' segments thereof, and an application of the conjugate in a targeted therapy for the tumours such as colon cancer, etc. 2-imidogen tetrahydrothiophene (2-IT) and N-hydroxysuccinimide base-m-(N-maleimide base) benzoate (MBS) or other cross linking agent molecules are used as intermediates to couple monoclonal antibody 3G11 and the Fab' segments thereof for resisting type IV collagenase with lidamycin(LDM), and therefore, monoclonal antibody 3G11-LDM conjugate and Fab'-LDM conjugate are obtained. The immunohistochemical staining is carried out with colon cancer, lung cancer, oesophagus cancer, gastric cancer, mammary cancer and malignant tumors by using the monoclonal antibody 3G11, and expressions of the increase of the activity of type IV collagenase are displayed in the digestive tract tumours. The indirect ELISA method mensurates that both the monoclonal antibody 3G11 and Fab' segments thereof have a strong immunity combining capability when combined with human colon cancer HT-29, lung cancer PG, squamous cancer KB, colon cancer 26 (C26) and liver cancer 22 (H22), and the monoclonal antibody 3G11 can generate a clear immunization video picture for the human FG lung cancer transplanted into a nude mouse. Experiments in vivo are used for curing mouse colon cancer and liver cancer, compared with free LDM in the same dosage, both monoclonal antibody 3G11-LDM conjugate and the Fab'-LDM conjugate show a stronger tumor growth inhibiting function. Therefore, 3G11-LDM conjugate and Fab'-LDM conjugate are possibly used for a targeted therapy for malignant tumors such as colon cancer, etc.
Manual wheelchairs (MWCs) are widely used by children with physical disabilities, yet many of these children are unable to use their wheelchair independently. Instead, they depend on others to push them. This dependency results in limited opportunities to decide what they want to do and where they want to go, leading to learned helplessness, social isolation, decreased participation, and restricted involvement in physical activities. Furthermore, unsafe MWC use increases the risk of injury, as highlighted by the 44,300 children treated each year in emergency departments for MWC-related injuries. While independent MWC mobility can positively influence quality of life, MWC skills training must also be provided to promote safe, independent MWC use. The effectiveness of MWC training programs for adults is well established, yet the current standard-of-care does not include MWC skills training for children and research regarding the efficacy of pediatric MWC skills training programs is limited. Skills on Wheels seeks to address these gaps and provide pilot data for a future large-scale, multi-site research project involving a randomized controlled trial. The final outcomes and significance of this project are as follows: Aim 1 is to explore the influence of Skills on Wheels on children's MWC skills and confidence in their MWC use and Aim 2 is to investigate the influence of Skills on Wheels on children's psychosocial skills, social participation, and adaptive behavior.
Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
The embodiment of the invention relates to a canine adenovirus type 2 attenuated vaccine strain and application thereof, wherein the preservation number of the canine adenovirus type 2 attenuated vaccine strain is CGMCC No. 19992. The canine adenovirus type 2 (CAV2/15 strain) low virulent strain is an isolated natural low virulent strain and has the following advantages: it has high culture toxicity value, and is stable at 10 per ml  9   .   0  TCID  50  Per ml; it has low immunizing dose, and minimum immunizing dose of 10  3   .   0  TCID  50  Use of 10  5   .   0  TCID  50  Good immune effect can be achieved; it can be used for various kinds of dogs of various ages, and can also be used for pregnant dogs; it is safe to use, and overdose injection (injection of 20 times the immunization dose) is still safe for dogs.
Participants will receive placebo during the double-blind period. After the DB period, participants enter the RTE period to receive vutrisiran 25 mg SC q3M or vutrisiran 50 mg SC q6M. After implementation of Amendment 4, participants from the DB period will enter the OLE period to receive vutrisiran 25 mg SC q3M and participants who were previously receiving vutrisiran 50 mg q6M in the RTE period, will be transitioned to vutrisiran 25 mg q3M in the OLE period.
Ureteroscopy (URS) is an up-to-date method that is widely used in the diagnosis and treatment of ureteral diseases. Apart from the diagnostic purposes of URS, the most common use is to intervene in ureteral stones. The vast majority of ureteral stones are treated endoscopically. A Double-J (DJ) stent is often placed after ureteroscopy. The purpose of the stent is to prevent obstruction, renal colic, and deterioration of renal function. The fact that the DJ stent will remain in the patient for a certain period of time (approximately 3-4 weeks) causes anxiety in the patient. However, approximately 80% of patients with DJ stent implantation have urinary system symptoms that impair their quality of life. Frequent urination (50-60%), sudden urge to urinate (57-60%), pain on urination (40%), incomplete evacuation (76%), flank pain (19-32%), suprapubic pain (30%) , incontinence and hematuria (25%) are the symptoms seen. Patients with DJ stent implanted after ureteroscopy surgery need more information, support, explanation and help to cope with the effects of these symptoms in the clinic and at home. In this context, it is important to provide an individualized and comprehensive education that includes the home care process before and after the URS. It has been determined in the literature that training before surgery reduces anxiety, pain level, complication and depression rates, and increases patient satisfaction in the postoperative period. No study has been found in the literature examining the effects of education given to patients with URS on their post-operative anxiety and readiness for discharge. In this context, this study will provide evidence-based data to the literature by investigating the effects of training given to patients with URS and DJ stent implantation on pre- and postoperative anxiety and readiness for discharge.
The Dan River Region (DRR) is a federally designated medically under-served area/population with high rates of obesity. In response to 3 comprehensive community needs assessments The Dan River Partnership for a Healthy Community (DRPHC) was established in 2010 'to foster community partnership to combat obesity in the Dan River Region through healthy lifestyle initiatives' (DRPHC mission statement). To date the DRPHC (1) tested a successful adult weight control intervention, (2) initiated youth-focus community garden and instant recess initiatives, and (3) continues to complete a comprehensive audit of the food and physical activity environment across the DRR. This RFA provided an opportunity to address an additional and complimentary area of need for the DRPHC-childhood obesity. A newly formed subcommittee and community advisory board (CAB) of the DRPHC, Partnering for Obesity Planning and Sustainability (POPS), met in preparation of this proposal and discussed the need to engage systems where high need families received services and could participate in childhood obesity treatment. The POPS-CAB came to consensus that using a systems-based approach, within the existing CBPR partnership would allow for the development of a contextually relevant intervention with the potential for long-term sustainability. Systems-based approaches include, but also move beyond, a focus on initiative effectiveness and address broader contextual issues such as initiative adoption, implementation, and maintenance across settings and delivery staff as well as reach and maintenance of effects at the individual level. The general goal of this proposal is to engage multiple systems through the DRPHC POPS-CAB and design and test prototype childhood obesity interventions. The current membership of the POPS-CAB include Danville Pittsylvania Health District, Children's Healthcare Center, Danville Parks Recreation \& Tourism, and Boys \& Girls Club, along with an interdisciplinary team of academic investigators. The first aim is to assess community capacity to develop, implement, and sustain a childhood obesity reduction initiative in the DRR. To accomplish this aim a concurrent mixed-method study design will be used and guided dimensions of community capacity and organizational level dimensions of the RE-AIM framework (i.e., adoption, implementation, and maintenance). The second aim is to determine the potential reach, effectiveness, feasibility and cost of the newly developed interventions. Three stages of iterative intervention testing/formative feedback loops in a public health and healthcare system will be used to achieve this aim. The partnership members will meet in an ongoing basis to discuss the qualitative \& quantitative results and make adaptations to improve the strategies. Indicators of success include reduced child BMI z-scores, the engagement of multiple systems, and regional capacity to evaluate research evidence and integrate this evidence into sustainable practices. The end goal is a childhood obesity intervention that is ready for large scale testing across these systems in the DRR.
The present invention provides a new purpose of triethylenetetraamine in the drug aspect, which more specifically provides an application of triethylenetetraamine as an antineoplastic auxiliary medicaement. Triethylenetetraamine as a telomerase inhibitor is used as an auxiliary medicament for treating or preventing tumor diseases, and is matched with a conventional antineoplastic medicament. The conventional antineoplastic medicament comprises adriamycin, carboplatin and paclitaxel. The tumor diseases comprise uterine cervix cancer, liver cancer, mammary cancer, etc. The triethylenetetraamine is matched with the conventional antineoplastic medicament, and the equal antineoplastic effect is achieved under the condition of reducing the medicament dosage. The medicament dosage of the antineoplastic medicament under the condition of clinical use is favorably reduced, and the toxic or side effect of the antineoplastic medicament on other organs or systems is reduced.